Clinical trials: Thyroid Associated Orbitopathy
Thyroid Eye Disease (TED)
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
- Trial name
- NCT06812325
- Testing
- VRDN-003
- Where
- 64 sites in United States, France and 5 more
- Volunteers
- 320 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
- Trial name
- REVEAL-1 (NCT06625411)
- Testing
- VRDN-003
- Where
- 48 sites in United States, Germany and 3 more
- Volunteers
- 132 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease, Graves Orbitopathy
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- NCT06112340
- Testing
- linsitinib
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sling Therapeutics, Inc.
Thyroid Associated Ophthalmopathy
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
Graves' orbitopathy (GO) is a disfiguring and disabling disease that profoundly impairs the quality of life of affected patients.
- Trial name
- ORGO (NCT03098225)
- Testing
- Orbital radiotherapy, Methylprednisolone
- Volunteers
- 120 people
- Sponsor
- University of Pisa
Thyroid Associated Orbitopathy
OCT Angiography Drived Alterations in Thyroid-associated Orbitopathy
The aim of this observational study is to evaluate retinal microvascular alterations in patients with thyroid-associated orbitopathy (TAO) using optical coherence tomography angiography (OCTA).
- Trial name
- TAO (NCT07341347)
- Where
- Croatia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Osijek University Hospital
Thyroid Eye Disease, Graves Ophthalmopathy
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy
- Trial name
- NCT06226545
- Testing
- LASN01
- Where
- 15 sites in United States, Spain and 1 more
- Volunteers
- 41 people
- Sponsor
- Lassen Therapeutics Inc.
Thyroid Associated Orbitopathy
Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections
The study objective is to investigate the efficacy and safety of periocular injections of methotrexate in management of patients with active moderate to severe thyroid associated orbitopathy in comparison to periocular injections…
- Trial name
- TOMATO (NCT05429450)
- Testing
- Methotrexate, Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 18 people
- Sponsor
- Cairo University
Thyroid Associated Orbitopathy
Changes in Orbital Macrovascular and Intraocular Microvascular Blood Flow After Orbital Decompression Surgery in Patients With Thyroid Eye Disease
This study aims to evaluate the effects of balanced orbital decompression surgery in patients with inactive thyroid-associated orbitopathy.
- Trial name
- BOD-VASC (NCT07393230)
- Testing
- Balanced Orbital Decompression Surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Thyroid Eye Disease
Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid Dysfunction
This study was conducted to develop an AI solution to evaluate clinical activity score (CAS) of thyroid associated orbitopathy (TAO) using periocular selfie images taken by smartphones in patients with thyroid dysfunction.
- Trial name
- NCT05731154
- Testing
- taking periorbital selfie images using smartphones
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Bundang Hospital
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease (TED), Graves Ophthalmopathy
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical…
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Trial name
- THYROSCOPE-TED (NCT07623993)
- Testing
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- THYROSCOPE INC.
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid-Associated Ophthalmopathy
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity.
- Trial name
- NCT06927375
- Testing
- Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University